ferric-carboxymaltose and Fatigue-Syndrome--Chronic

Prospective, randomized, controlled, single-centre trial. (ClinicalTrials.gov: NCT01787526).. Tertiary care center in Graz, Austria.. 176 (138 female and 38 male) whole-blood and platelet apheresis donors aged ≥ 18 and ≤ 65 years with iron deficiency (ferritin ≤ 30ng/mL at the time of blood donation).. Intravenous iron (1 g ferric carboxymaltose, n = 86) or oral iron supplementation (10 g iron fumarate, 100 capsules, n = 90).. Clinical symptoms were evaluated by a survey before iron therapy (visit 0, V0) and after 8-12 weeks (visit 1, V1), including questions about symptoms of restless legs syndrome (RLS), chronic fatigue syndrome (CFS), sleeping disorders, quality of life and symptoms like headaches, dyspnoea, dizziness, palpitations, pica and trophic changes in fingernails or hair.. We found a significant improvement in the severity of symptoms for RLS, fatigue and sleep quality (. Iron supplementation in iron-deficient blood donors may be an effective strategy to improve symptoms related to iron deficiency and the wellbeing of blood donors.

Topics: Administration, Oral; Adolescent; Adult; Aged; Anemia, Iron-Deficiency; Blood Donors; Dietary Supplements; Fatigue Syndrome, Chronic; Female; Ferric Compounds; Humans; Infusions, Intravenous; Iron, Dietary; Male; Maltose; Middle Aged; Quality of Life; Restless Legs Syndrome; Severity of Illness Index; Sleep Wake Disorders; Treatment Outcome; Young Adult